APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pancreatic Endocrine Tumor Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Pancreatic Endocrine Tumor Drug Market Analysis and Forecast 2026-2032

26 December 2025196 pages

Choose your research edition.

Industry ResearchPancreatic Endocrine Tumor Drug Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Pancreatic Endocrine Tumor Drug Industry Growth and Trends Forecast to 203291 pages · $3,450 USDMarket StructureGlobal Pancreatic Endocrine Tumor Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pancreatic Endocrine Tumor Drug Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Pancreatic Endocrine Tumor Drug Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Pancreatic Endocrine Tumor Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Pancreatic Endocrine Tumor Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Pancreatic Endocrine Tumor Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Pancreatic Endocrine Tumor Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Pancreatic Endocrine Tumor Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Pancreatic Endocrine Tumor Drug include Ipsen S.A., MediaPharma s.r.l., OXiGENE, Inc., Jiangsu Hengrui Medicine Co., Ltd. and Novartis AG, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Pancreatic Endocrine Tumor Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Pancreatic Endocrine Tumor Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Pancreatic Endocrine Tumor Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Pancreatic Endocrine Tumor Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Pancreatic Endocrine Tumor Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Pancreatic Endocrine Tumor Drug sales, projected growth trends, production technology, application and end-user industry.

Pancreatic Endocrine Tumor Drug Segment by Company

Ipsen S.A.

MediaPharma s.r.l.

OXiGENE, Inc.

Jiangsu Hengrui Medicine Co., Ltd.

Novartis AG

Pancreatic Endocrine Tumor Drug Segment by Type

Buparlisib Hydrochloride

Dovitinib Lactate

Fosbretabulin Tromethamine

Lanreotide Acetate

MPHE-001B

Others

Pancreatic Endocrine Tumor Drug Segment by Application

Clinic

Research Center

Hospital

Pancreatic Endocrine Tumor Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pancreatic Endocrine Tumor Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pancreatic Endocrine Tumor Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pancreatic Endocrine Tumor Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Pancreatic Endocrine Tumor Drug in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Pancreatic Endocrine Tumor Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Pancreatic Endocrine Tumor Drug sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Pancreatic Endocrine Tumor Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Buparlisib Hydrochloride Major Manufacturers Table 3. Dovitinib Lactate Major Manufacturers Table 4. Fosbretabulin Tromethamine Major Manufacturers Table 5. Lanreotide Acetate Major Manufacturers Table 6. MPHE-001B Major Manufacturers Table 7. Others Major Manufacturers Table 8. Global Pancreatic Endocrine Tumor Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 9. Clinic Major Manufacturers Table 10. Research Center Major Manufacturers Table 11. Hospital Major Manufacturers Table 12. Pancreatic Endocrine Tumor Drug Industry Trends Table 13. Pancreatic Endocrine Tumor Drug Industry Drivers Table 14. Pancreatic Endocrine Tumor Drug Industry Opportunities and Challenges Table 15. Pancreatic Endocrine Tumor Drug Industry Restraints Table 16. Global Pancreatic Endocrine Tumor Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Pancreatic Endocrine Tumor Drug Revenue by Region (2021-2026) & (US$ Million) Table 18. Global Pancreatic Endocrine Tumor Drug Revenue by Region (2027-2032) & (US$ Million) Table 19. Global Pancreatic Endocrine Tumor Drug Revenue Market Share by Region (2021-2026) Table 20. Global Pancreatic Endocrine Tumor Drug Revenue Market Share by Region (2027-2032) Table 21. Global Pancreatic Endocrine Tumor Drug Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (W Units) Table 22. Global Pancreatic Endocrine Tumor Drug Sales by Region (2021-2026) & (W Units) Table 23. Global Pancreatic Endocrine Tumor Drug Sales by Region (2027-2032) & (W Units) Table 24. Global Pancreatic Endocrine Tumor Drug Sales Market Share by Region (2021-2026) Table 25. Global Pancreatic Endocrine Tumor Drug Sales Market Share by Region (2027-2032) Table 26. Global Pancreatic Endocrine Tumor Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Pancreatic Endocrine Tumor Drug Revenue Market Share by Manufacturers (2021-2026) Table 28. Global Pancreatic Endocrine Tumor Drug Sales by Manufacturers (US$ Million) & (2021-2026) Table 29. Global Pancreatic Endocrine Tumor Drug Sales Market Share by Manufacturers (2021-2026) Table 30. Global Pancreatic Endocrine Tumor Drug Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 31. Global Pancreatic Endocrine Tumor Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 32. Global Pancreatic Endocrine Tumor Drug Key Manufacturers Manufacturing Sites & Headquarters Table 33. Global Pancreatic Endocrine Tumor Drug Manufacturers, Product Type & Application Table 34. Global Pancreatic Endocrine Tumor Drug Manufacturers' Establishment Date Table 35. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 36. Global Pancreatic Endocrine Tumor Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 37. Global Pancreatic Endocrine Tumor Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Pancreatic Endocrine Tumor Drug Revenue by Type (2021-2026) & (US$ Million) Table 39. Global Pancreatic Endocrine Tumor Drug Revenue by Type (2027-2032) & (US$ Million) Table 40. Global Pancreatic Endocrine Tumor Drug Revenue Market Share by Type (2021-2026) Table 41. Global Pancreatic Endocrine Tumor Drug Revenue Market Share by Type (2027-2032) Table 42. Global Pancreatic Endocrine Tumor Drug Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 43. Global Pancreatic Endocrine Tumor Drug Sales by Type (2021-2026) & (W Units) Table 44. Global Pancreatic Endocrine Tumor Drug Sales by Type (2027-2032) & (W Units) Table 45. Global Pancreatic Endocrine Tumor Drug Sales Market Share by Type (2021-2026) Table 46. Global Pancreatic Endocrine Tumor Drug Sales Market Share by Type (2027-2032) Table 47. Global Pancreatic Endocrine Tumor Drug Price by Type (2021-2026) & (US$/Unit) Table 48. Global Pancreatic Endocrine Tumor Drug Price by Type (2027-2032) & (US$/Unit) Table 49. Global Pancreatic Endocrine Tumor Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Pancreatic Endocrine Tumor Drug Revenue by Application (2021-2026) & (US$ Million) Table 51. Global Pancreatic Endocrine Tumor Drug Revenue by Application (2027-2032) & (US$ Million) Table 52. Global Pancreatic Endocrine Tumor Drug Revenue Market Share by Application (2021-2026) Table 53. Global Pancreatic Endocrine Tumor Drug Revenue Market Share by Application (2027-2032) Table 54. Global Pancreatic Endocrine Tumor Drug Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 55. Global Pancreatic Endocrine Tumor Drug Sales by Application (2021-2026) & (W Units) Table 56. Global Pancreatic Endocrine Tumor Drug Sales by Application (2027-2032) & (W Units) Table 57. Global Pancreatic Endocrine Tumor Drug Sales Market Share by Application (2021-2026) Table 58. Global Pancreatic Endocrine Tumor Drug Sales Market Share by Application (2027-2032) Table 59. Global Pancreatic Endocrine Tumor Drug Price by Application (2021-2026) & (US$/Unit) Table 60. Global Pancreatic Endocrine Tumor Drug Price by Application (2027-2032) & (US$/Unit) Table 61. Ipsen S.A. Company Information Table 62. Ipsen S.A. Business Overview Table 63. Ipsen S.A. Pancreatic Endocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 64. Ipsen S.A. Pancreatic Endocrine Tumor Drug Product Portfolio Table 65. Ipsen S.A. Recent Development Table 66. MediaPharma s.r.l. Company Information Table 67. MediaPharma s.r.l. Business Overview Table 68. MediaPharma s.r.l. Pancreatic Endocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. MediaPharma s.r.l. Pancreatic Endocrine Tumor Drug Product Portfolio Table 70. MediaPharma s.r.l. Recent Development Table 71. OXiGENE, Inc. Company Information Table 72. OXiGENE, Inc. Business Overview Table 73. OXiGENE, Inc. Pancreatic Endocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. OXiGENE, Inc. Pancreatic Endocrine Tumor Drug Product Portfolio Table 75. OXiGENE, Inc. Recent Development Table 76. Jiangsu Hengrui Medicine Co., Ltd. Company Information Table 77. Jiangsu Hengrui Medicine Co., Ltd. Business Overview Table 78. Jiangsu Hengrui Medicine Co., Ltd. Pancreatic Endocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Jiangsu Hengrui Medicine Co., Ltd. Pancreatic Endocrine Tumor Drug Product Portfolio Table 80. Jiangsu Hengrui Medicine Co., Ltd. Recent Development Table 81. Novartis AG Company Information Table 82. Novartis AG Business Overview Table 83. Novartis AG Pancreatic Endocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Novartis AG Pancreatic Endocrine Tumor Drug Product Portfolio Table 85. Novartis AG Recent Development Table 86. North America Pancreatic Endocrine Tumor Drug Revenue by Type (2021-2026) & (US$ Million) Table 87. North America Pancreatic Endocrine Tumor Drug Revenue by Type (2027-2032) & (US$ Million) Table 88. North America Pancreatic Endocrine Tumor Drug Sales by Type (2021-2026) & (W Units) Table 89. North America Pancreatic Endocrine Tumor Drug Sales by Type (2027-2032) & (W Units) Table 90. North America Pancreatic Endocrine Tumor Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 91. North America Pancreatic Endocrine Tumor Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 92. North America Pancreatic Endocrine Tumor Drug Revenue by Application (2021-2026) & (US$ Million) Table 93. North America Pancreatic Endocrine Tumor Drug Revenue by Application (2027-2032) & (US$ Million) Table 94. North America Pancreatic Endocrine Tumor Drug Sales by Application (2021-2026) & (W Units) Table 95. North America Pancreatic Endocrine Tumor Drug Sales by Application (2027-2032) & (W Units) Table 96. North America Pancreatic Endocrine Tumor Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 97. North America Pancreatic Endocrine Tumor Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 98. North America Pancreatic Endocrine Tumor Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 99. North America Pancreatic Endocrine Tumor Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 100. North America Pancreatic Endocrine Tumor Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 101. North America Pancreatic Endocrine Tumor Drug Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 102. North America Pancreatic Endocrine Tumor Drug Sales by Country (2021-2026) & (W Units) Table 103. North America Pancreatic Endocrine Tumor Drug Sales by Country (2027-2032) & (W Units) Table 104. North America Pancreatic Endocrine Tumor Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 105. North America Pancreatic Endocrine Tumor Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 106. United States Pancreatic Endocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 107. Canada Pancreatic Endocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 108. Mexico Pancreatic Endocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 109. Europe Pancreatic Endocrine Tumor Drug Revenue by Type (2021-2026) & (US$ Million) Table 110. Europe Pancreatic Endocrine Tumor Drug Revenue by Type (2027-2032) & (US$ Million) Table 111. Europe Pancreatic Endocrine Tumor Drug Sales by Type (2021-2026) & (W Units) Table 112. Europe Pancreatic Endocrine Tumor Drug Sales by Type (2027-2032) & (W Units) Table 113. Europe Pancreatic Endocrine Tumor Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 114. Europe Pancreatic Endocrine Tumor Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 115. Europe Pancreatic Endocrine Tumor Drug Revenue by Application (2021-2026) & (US$ Million) Table 116. Europe Pancreatic Endocrine Tumor Drug Revenue by Application (2027-2032) & (US$ Million) Table 117. Europe Pancreatic Endocrine Tumor Drug Sales by Application (2021-2026) & (W Units) Table 118. Europe Pancreatic Endocrine Tumor Drug Sales by Application (2027-2032) & (W Units) Table 119. Europe Pancreatic Endocrine Tumor Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 120. Europe Pancreatic Endocrine Tumor Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 121. Europe Pancreatic Endocrine Tumor Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 122. Europe Pancreatic Endocrine Tumor Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 123. Europe Pancreatic Endocrine Tumor Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 124. Europe Pancreatic Endocrine Tumor Drug Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 125. Europe Pancreatic Endocrine Tumor Drug Sales by Country (2021-2026) & (W Units) Table 126. Europe Pancreatic Endocrine Tumor Drug Sales by Country (2027-2032) & (W Units) Table 127. Europe Pancreatic Endocrine Tumor Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 128. Europe Pancreatic Endocrine Tumor Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 129. Germany Pancreatic Endocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 130. France Pancreatic Endocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 131. U.K. Pancreatic Endocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 132. Italy Pancreatic Endocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 133. Russia Pancreatic Endocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 134. Spain Pancreatic Endocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 135. Netherlands Pancreatic Endocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 136. Switzerland Pancreatic Endocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 137. Sweden Pancreatic Endocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 138. Poland Pancreatic Endocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 139. China Pancreatic Endocrine Tumor Drug Revenue by Type (2021-2026) & (US$ Million) Table 140. China Pancreatic Endocrine Tumor Drug Revenue by Type (2027-2032) & (US$ Million) Table 141. China Pancreatic Endocrine Tumor Drug Sales by Type (2021-2026) & (W Units) Table 142. China Pancreatic Endocrine Tumor Drug Sales by Type (2027-2032) & (W Units) Table 143. China Pancreatic Endocrine Tumor Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 144. China Pancreatic Endocrine Tumor Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 145. China Pancreatic Endocrine Tumor Drug Revenue by Application (2021-2026) & (US$ Million) Table 146. China Pancreatic Endocrine Tumor Drug Revenue by Application (2027-2032) & (US$ Million) Table 147. China Pancreatic Endocrine Tumor Drug Sales by Application (2021-2026) & (W Units) Table 148. China Pancreatic Endocrine Tumor Drug Sales by Application (2027-2032) & (W Units) Table 149. China Pancreatic Endocrine Tumor Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 150. China Pancreatic Endocrine Tumor Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 151. Asia Pancreatic Endocrine Tumor Drug Revenue by Type (2021-2026) & (US$ Million) Table 152. Asia Pancreatic Endocrine Tumor Drug Revenue by Type (2027-2032) & (US$ Million) Table 153. Asia Pancreatic Endocrine Tumor Drug Sales by Type (2021-2026) & (W Units) Table 154. Asia Pancreatic Endocrine Tumor Drug Sales by Type (2027-2032) & (W Units) Table 155. Asia Pancreatic Endocrine Tumor Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 156. Asia Pancreatic Endocrine Tumor Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 157. Asia Pancreatic Endocrine Tumor Drug Revenue by Application (2021-2026) & (US$ Million) Table 158. Asia Pancreatic Endocrine Tumor Drug Revenue by Application (2027-2032) & (US$ Million) Table 159. Asia Pancreatic Endocrine Tumor Drug Sales by Application (2021-2026) & (W Units) Table 160. Asia Pancreatic Endocrine Tumor Drug Sales by Application (2027-2032) & (W Units) Table 161. Asia Pancreatic Endocrine Tumor Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 162. Asia Pancreatic Endocrine Tumor Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 163. Asia Pancreatic Endocrine Tumor Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 164. Asia Pancreatic Endocrine Tumor Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 165. Asia Pancreatic Endocrine Tumor Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 166. Asia Pancreatic Endocrine Tumor Drug Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 167. Asia Pancreatic Endocrine Tumor Drug Sales by Country (2021-2026) & (W Units) Table 168. Asia Pancreatic Endocrine Tumor Drug Sales by Country (2027-2032) & (W Units) Table 169. Asia Pancreatic Endocrine Tumor Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 170. Asia Pancreatic Endocrine Tumor Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 171. Japan Pancreatic Endocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 172. South Korea Pancreatic Endocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 173. India Pancreatic Endocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 174. Australia Pancreatic Endocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 175. Taiwan Pancreatic Endocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 176. Southeast Asia Pancreatic Endocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 177. SAMEA Pancreatic Endocrine Tumor Drug Revenue by Type (2021-2026) & (US$ Million) Table 178. SAMEA Pancreatic Endocrine Tumor Drug Revenue by Type (2027-2032) & (US$ Million) Table 179. SAMEA Pancreatic Endocrine Tumor Drug Sales by Type (2021-2026) & (W Units) Table 180. SAMEA Pancreatic Endocrine Tumor Drug Sales by Type (2027-2032) & (W Units) Table 181. SAMEA Pancreatic Endocrine Tumor Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 182. SAMEA Pancreatic Endocrine Tumor Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 183. SAMEA Pancreatic Endocrine Tumor Drug Revenue by Application (2021-2026) & (US$ Million) Table 184. SAMEA Pancreatic Endocrine Tumor Drug Revenue by Application (2027-2032) & (US$ Million) Table 185. SAMEA Pancreatic Endocrine Tumor Drug Sales by Application (2021-2026) & (W Units) Table 186. SAMEA Pancreatic Endocrine Tumor Drug Sales by Application (2027-2032) & (W Units) Table 187. SAMEA Pancreatic Endocrine Tumor Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 188. SAMEA Pancreatic Endocrine Tumor Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 189. SAMEA Pancreatic Endocrine Tumor Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 190. SAMEA Pancreatic Endocrine Tumor Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 191. SAMEA Pancreatic Endocrine Tumor Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 192. SAMEA Pancreatic Endocrine Tumor Drug Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 193. SAMEA Pancreatic Endocrine Tumor Drug Sales by Country (2021-2026) & (W Units) Table 194. SAMEA Pancreatic Endocrine Tumor Drug Sales by Country (2027-2032) & (W Units) Table 195. SAMEA Pancreatic Endocrine Tumor Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 196. SAMEA Pancreatic Endocrine Tumor Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 197. Brazil Pancreatic Endocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 198. Argentina Pancreatic Endocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 199. Chile Pancreatic Endocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 200. Colombia Pancreatic Endocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 201. Peru Pancreatic Endocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 202. Saudi Arabia Pancreatic Endocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 203. Israel Pancreatic Endocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 204. UAE Pancreatic Endocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 205. Turkey Pancreatic Endocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 206. Iran Pancreatic Endocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 207. Egypt Pancreatic Endocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 208. Key Raw Materials Table 209. Raw Materials Key Suppliers Table 210. Pancreatic Endocrine Tumor Drug Distributors List Table 211. Pancreatic Endocrine Tumor Drug Customers List Table 212. Research Programs/Design for This Report Table 213. Authors List of This Report Table 214. Secondary Sources Table 215. Primary Sources List of Figures Figure 1. Pancreatic Endocrine Tumor Drug Image Figure 2. Global Pancreatic Endocrine Tumor Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pancreatic Endocrine Tumor Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. Buparlisib Hydrochloride Image Figure 5. Dovitinib Lactate Image Figure 6. Fosbretabulin Tromethamine Image Figure 7. Lanreotide Acetate Image Figure 8. MPHE-001B Image Figure 9. Others Image Figure 10. Global Pancreatic Endocrine Tumor Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Pancreatic Endocrine Tumor Drug Market Size Share 2021 VS 2025 VS 2032 Figure 12. Clinic Image Figure 13. Research Center Image Figure 14. Hospital Image Figure 15. Global Pancreatic Endocrine Tumor Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Pancreatic Endocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Figure 17. Global Pancreatic Endocrine Tumor Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Pancreatic Endocrine Tumor Drug Revenue Market Share by Region: 2025 Versus 2032 Figure 19. Global Pancreatic Endocrine Tumor Drug Revenue Market Share by Region (2021-2032) Figure 20. Global Pancreatic Endocrine Tumor Drug Sales (2021-2032) & (W Units) Figure 21. Global Pancreatic Endocrine Tumor Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 22. Global Pancreatic Endocrine Tumor Drug Sales Market Share by Region (2021-2032) Figure 23. US & Canada & Mexico Pancreatic Endocrine Tumor Drug Sales YoY (2021-2032) & (W Units) Figure 24. Europe Pancreatic Endocrine Tumor Drug Sales YoY (2021-2032) & (W Units) Figure 25. China Pancreatic Endocrine Tumor Drug Sales YoY (2021-2032) & (W Units) Figure 26. Asia (Excluding China) Pancreatic Endocrine Tumor Drug Sales YoY (2021-2032) & (W Units) Figure 27. South America, Middle East and Africa Pancreatic Endocrine Tumor Drug Sales YoY (2021-2032) & (W Units) Figure 28. Global Pancreatic Endocrine Tumor Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 29. Global Pancreatic Endocrine Tumor Drug Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 30. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 31. Global Pancreatic Endocrine Tumor Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 32. Global Pancreatic Endocrine Tumor Drug Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 33. Global Pancreatic Endocrine Tumor Drug Revenue Market Share by Type (2021-2032) Figure 34. Global Pancreatic Endocrine Tumor Drug Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 35. Global Pancreatic Endocrine Tumor Drug Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 36. Global Pancreatic Endocrine Tumor Drug Sales Market Share by Type (2021-2032) Figure 37. Global Pancreatic Endocrine Tumor Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 38. Global Pancreatic Endocrine Tumor Drug Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 39. Global Pancreatic Endocrine Tumor Drug Revenue Market Share by Application (2021-2032) Figure 40. Global Pancreatic Endocrine Tumor Drug Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 41. Global Pancreatic Endocrine Tumor Drug Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 42. Global Pancreatic Endocrine Tumor Drug Sales Market Share by Application (2021-2032) Figure 43. North America Pancreatic Endocrine Tumor Drug Revenue Share by Type (2021-2032) Figure 44. North America Pancreatic Endocrine Tumor Drug Sales Share by Type (2021-2032) Figure 45. North America Pancreatic Endocrine Tumor Drug Revenue Share by Application (2021-2032) Figure 46. North America Pancreatic Endocrine Tumor Drug Sales Share by Application (2021-2032) Figure 47. North America Pancreatic Endocrine Tumor Drug Revenue Share by Country (2021-2032) Figure 48. North America Pancreatic Endocrine Tumor Drug Sales Share by Country (2021-2032) Figure 49. Europe Pancreatic Endocrine Tumor Drug Revenue Share by Type (2021-2032) Figure 50. Europe Pancreatic Endocrine Tumor Drug Sales Share by Type (2021-2032) Figure 51. Europe Pancreatic Endocrine Tumor Drug Revenue Share by Application (2021-2032) Figure 52. Europe Pancreatic Endocrine Tumor Drug Sales Share by Application (2021-2032) Figure 53. Europe Pancreatic Endocrine Tumor Drug Revenue Share by Country (2021-2032) Figure 54. Europe Pancreatic Endocrine Tumor Drug Sales Share by Country (2021-2032) Figure 55. China Pancreatic Endocrine Tumor Drug Revenue Share by Type (2021-2032) Figure 56. China Pancreatic Endocrine Tumor Drug Sales Share by Type (2021-2032) Figure 57. China Pancreatic Endocrine Tumor Drug Revenue Share by Application (2021-2032) Figure 58. China Pancreatic Endocrine Tumor Drug Sales Share by Application (2021-2032) Figure 59. Asia Pancreatic Endocrine Tumor Drug Revenue Share by Type (2021-2032) Figure 60. Asia Pancreatic Endocrine Tumor Drug Sales Share by Type (2021-2032) Figure 61. Asia Pancreatic Endocrine Tumor Drug Revenue Share by Application (2021-2032) Figure 62. Asia Pancreatic Endocrine Tumor Drug Sales Share by Application (2021-2032) Figure 63. Asia Pancreatic Endocrine Tumor Drug Revenue Share by Country (2021-2032) Figure 64. Asia Pancreatic Endocrine Tumor Drug Sales Share by Country (2021-2032) Figure 65. SAMEA Pancreatic Endocrine Tumor Drug Revenue Share by Type (2021-2032) Figure 66. SAMEA Pancreatic Endocrine Tumor Drug Sales Share by Type (2021-2032) Figure 67. SAMEA Pancreatic Endocrine Tumor Drug Revenue Share by Application (2021-2032) Figure 68. SAMEA Pancreatic Endocrine Tumor Drug Sales Share by Application (2021-2032) Figure 69. SAMEA Pancreatic Endocrine Tumor Drug Revenue Share by Country (2021-2032) Figure 70. SAMEA Pancreatic Endocrine Tumor Drug Sales Share by Country (2021-2032) Figure 71. Pancreatic Endocrine Tumor Drug Value Chain Figure 72. Manufacturing Cost Structure Figure 73. Pancreatic Endocrine Tumor Drug Production Mode & Process Figure 74. Direct Comparison with Distribution Share Figure 75. Distributors Profiles Figure 76. Years Considered Figure 77. Research Process Figure 78. Key Executives Interviewed

Scope & coverage.

Types
  • Buparlisib Hydrochloride
  • Dovitinib Lactate
  • Fosbretabulin Tromethamine
  • Lanreotide Acetate
  • MPHE-001B
  • Others
Applications
  • Clinic
  • Research Center
  • Hospital
Companies covered
  • Ipsen S.A.
  • MediaPharma s.r.l.
  • OXiGENE, Inc.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Novartis AG

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Pancreatic Endocrine Tumor Drug Market by Type
  3. 1.2.1 Global Pancreatic Endocrine Tumor Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Buparlisib Hydrochloride
  5. 1.2.3 Dovitinib Lactate
  6. 1.2.4 Fosbretabulin Tromethamine
  7. 1.2.5 Lanreotide Acetate
  8. 1.2.6 MPHE-001B
  9. 1.2.7 Others
  10. 1.3 Pancreatic Endocrine Tumor Drug Market by Application
  11. 1.3.1 Global Pancreatic Endocrine Tumor Drug Market Size by Application, 2021 VS 2025 VS 2032
  12. 1.3.2 Clinic
  13. 1.3.3 Research Center
  14. 1.3.4 Hospital
  15. 1.4 Assumptions and Limitations
  16. 1.5 Study Goals and Objectives
2 Pancreatic Endocrine Tumor Drug Market Dynamics
  1. 2.1 Pancreatic Endocrine Tumor Drug Industry Trends
  2. 2.2 Pancreatic Endocrine Tumor Drug Industry Drivers
  3. 2.3 Pancreatic Endocrine Tumor Drug Industry Opportunities and Challenges
  4. 2.4 Pancreatic Endocrine Tumor Drug Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Pancreatic Endocrine Tumor Drug Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Pancreatic Endocrine Tumor Drug Revenue by Region
  3. 3.2.1 Global Pancreatic Endocrine Tumor Drug Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Pancreatic Endocrine Tumor Drug Revenue by Region (2021-2026)
  5. 3.2.3 Global Pancreatic Endocrine Tumor Drug Revenue by Region (2027-2032)
  6. 3.2.4 Global Pancreatic Endocrine Tumor Drug Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Pancreatic Endocrine Tumor Drug Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Pancreatic Endocrine Tumor Drug Sales by Region
  9. 3.4.1 Global Pancreatic Endocrine Tumor Drug Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Pancreatic Endocrine Tumor Drug Sales by Region (2021-2026)
  11. 3.4.3 Global Pancreatic Endocrine Tumor Drug Sales by Region (2027-2032)
  12. 3.4.4 Global Pancreatic Endocrine Tumor Drug Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Pancreatic Endocrine Tumor Drug Revenue by Manufacturers
  2. 4.1.1 Global Pancreatic Endocrine Tumor Drug Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Pancreatic Endocrine Tumor Drug Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Pancreatic Endocrine Tumor Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Pancreatic Endocrine Tumor Drug Sales by Manufacturers
  6. 4.2.1 Global Pancreatic Endocrine Tumor Drug Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Pancreatic Endocrine Tumor Drug Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Pancreatic Endocrine Tumor Drug Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Pancreatic Endocrine Tumor Drug Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Pancreatic Endocrine Tumor Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Pancreatic Endocrine Tumor Drug Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Pancreatic Endocrine Tumor Drug Manufacturers, Product Type & Application
  13. 4.7 Global Pancreatic Endocrine Tumor Drug Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Pancreatic Endocrine Tumor Drug Market CR5 and HHI
  16. 4.8.2 2025 Pancreatic Endocrine Tumor Drug Tier 1, Tier 2, and Tier 3
5 Pancreatic Endocrine Tumor Drug Market by Type
  1. 5.1 Global Pancreatic Endocrine Tumor Drug Revenue by Type
  2. 5.1.1 Global Pancreatic Endocrine Tumor Drug Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Pancreatic Endocrine Tumor Drug Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Pancreatic Endocrine Tumor Drug Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Pancreatic Endocrine Tumor Drug Sales by Type
  6. 5.2.1 Global Pancreatic Endocrine Tumor Drug Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Pancreatic Endocrine Tumor Drug Sales by Type (2021-2032) & (W Units)
  8. 5.2.3 Global Pancreatic Endocrine Tumor Drug Sales Market Share by Type (2021-2032)
  9. 5.3 Global Pancreatic Endocrine Tumor Drug Price by Type
6 Pancreatic Endocrine Tumor Drug Market by Application
  1. 6.1 Global Pancreatic Endocrine Tumor Drug Revenue by Application
  2. 6.1.1 Global Pancreatic Endocrine Tumor Drug Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Pancreatic Endocrine Tumor Drug Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Pancreatic Endocrine Tumor Drug Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Pancreatic Endocrine Tumor Drug Sales by Application
  6. 6.2.1 Global Pancreatic Endocrine Tumor Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Pancreatic Endocrine Tumor Drug Sales by Application (2021-2032) & (W Units)
  8. 6.2.3 Global Pancreatic Endocrine Tumor Drug Sales Market Share by Application (2021-2032)
  9. 6.3 Global Pancreatic Endocrine Tumor Drug Price by Application
7 Company Profiles
  1. 7.1 Ipsen S.A.
  2. 7.1.1 Ipsen S.A. Company Information
  3. 7.1.2 Ipsen S.A. Business Overview
  4. 7.1.3 Ipsen S.A. Pancreatic Endocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Ipsen S.A. Pancreatic Endocrine Tumor Drug Product Portfolio
  6. 7.1.5 Ipsen S.A. Recent Developments
  7. 7.2 MediaPharma s.r.l.
  8. 7.2.1 MediaPharma s.r.l. Company Information
  9. 7.2.2 MediaPharma s.r.l. Business Overview
  10. 7.2.3 MediaPharma s.r.l. Pancreatic Endocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 MediaPharma s.r.l. Pancreatic Endocrine Tumor Drug Product Portfolio
  12. 7.2.5 MediaPharma s.r.l. Recent Developments
  13. 7.3 OXiGENE, Inc.
  14. 7.3.1 OXiGENE, Inc. Company Information
  15. 7.3.2 OXiGENE, Inc. Business Overview
  16. 7.3.3 OXiGENE, Inc. Pancreatic Endocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 OXiGENE, Inc. Pancreatic Endocrine Tumor Drug Product Portfolio
  18. 7.3.5 OXiGENE, Inc. Recent Developments
  19. 7.4 Jiangsu Hengrui Medicine Co., Ltd.
  20. 7.4.1 Jiangsu Hengrui Medicine Co., Ltd. Company Information
  21. 7.4.2 Jiangsu Hengrui Medicine Co., Ltd. Business Overview
  22. 7.4.3 Jiangsu Hengrui Medicine Co., Ltd. Pancreatic Endocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Jiangsu Hengrui Medicine Co., Ltd. Pancreatic Endocrine Tumor Drug Product Portfolio
  24. 7.4.5 Jiangsu Hengrui Medicine Co., Ltd. Recent Developments
  25. 7.5 Novartis AG
  26. 7.5.1 Novartis AG Company Information
  27. 7.5.2 Novartis AG Business Overview
  28. 7.5.3 Novartis AG Pancreatic Endocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Novartis AG Pancreatic Endocrine Tumor Drug Product Portfolio
  30. 7.5.5 Novartis AG Recent Developments
8 North America
  1. 8.1 North America Pancreatic Endocrine Tumor Drug Market Size by Type
  2. 8.1.1 North America Pancreatic Endocrine Tumor Drug Revenue by Type (2021-2032)
  3. 8.1.2 North America Pancreatic Endocrine Tumor Drug Sales by Type (2021-2032)
  4. 8.1.3 North America Pancreatic Endocrine Tumor Drug Price by Type (2021-2032)
  5. 8.2 North America Pancreatic Endocrine Tumor Drug Market Size by Application
  6. 8.2.1 North America Pancreatic Endocrine Tumor Drug Revenue by Application (2021-2032)
  7. 8.2.2 North America Pancreatic Endocrine Tumor Drug Sales by Application (2021-2032)
  8. 8.2.3 North America Pancreatic Endocrine Tumor Drug Price by Application (2021-2032)
  9. 8.3 North America Pancreatic Endocrine Tumor Drug Market Size by Country
  10. 8.3.1 North America Pancreatic Endocrine Tumor Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Pancreatic Endocrine Tumor Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Pancreatic Endocrine Tumor Drug Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Pancreatic Endocrine Tumor Drug Market Size by Type
  2. 9.1.1 Europe Pancreatic Endocrine Tumor Drug Revenue by Type (2021-2032)
  3. 9.1.2 Europe Pancreatic Endocrine Tumor Drug Sales by Type (2021-2032)
  4. 9.1.3 Europe Pancreatic Endocrine Tumor Drug Price by Type (2021-2032)
  5. 9.2 Europe Pancreatic Endocrine Tumor Drug Market Size by Application
  6. 9.2.1 Europe Pancreatic Endocrine Tumor Drug Revenue by Application (2021-2032)
  7. 9.2.2 Europe Pancreatic Endocrine Tumor Drug Sales by Application (2021-2032)
  8. 9.2.3 Europe Pancreatic Endocrine Tumor Drug Price by Application (2021-2032)
  9. 9.3 Europe Pancreatic Endocrine Tumor Drug Market Size by Country
  10. 9.3.1 Europe Pancreatic Endocrine Tumor Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Pancreatic Endocrine Tumor Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Pancreatic Endocrine Tumor Drug Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Pancreatic Endocrine Tumor Drug Market Size by Type
  2. 10.1.1 China Pancreatic Endocrine Tumor Drug Revenue by Type (2021-2032)
  3. 10.1.2 China Pancreatic Endocrine Tumor Drug Sales by Type (2021-2032)
  4. 10.1.3 China Pancreatic Endocrine Tumor Drug Price by Type (2021-2032)
  5. 10.2 China Pancreatic Endocrine Tumor Drug Market Size by Application
  6. 10.2.1 China Pancreatic Endocrine Tumor Drug Revenue by Application (2021-2032)
  7. 10.2.2 China Pancreatic Endocrine Tumor Drug Sales by Application (2021-2032)
  8. 10.2.3 China Pancreatic Endocrine Tumor Drug Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Pancreatic Endocrine Tumor Drug Market Size by Type
  2. 11.1.1 Asia Pancreatic Endocrine Tumor Drug Revenue by Type (2021-2032)
  3. 11.1.2 Asia Pancreatic Endocrine Tumor Drug Sales by Type (2021-2032)
  4. 11.1.3 Asia Pancreatic Endocrine Tumor Drug Price by Type (2021-2032)
  5. 11.2 Asia Pancreatic Endocrine Tumor Drug Market Size by Application
  6. 11.2.1 Asia Pancreatic Endocrine Tumor Drug Revenue by Application (2021-2032)
  7. 11.2.2 Asia Pancreatic Endocrine Tumor Drug Sales by Application (2021-2032)
  8. 11.2.3 Asia Pancreatic Endocrine Tumor Drug Price by Application (2021-2032)
  9. 11.3 Asia Pancreatic Endocrine Tumor Drug Market Size by Country
  10. 11.3.1 Asia Pancreatic Endocrine Tumor Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Pancreatic Endocrine Tumor Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Pancreatic Endocrine Tumor Drug Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Pancreatic Endocrine Tumor Drug Market Size by Type
  2. 12.1.1 SAMEA Pancreatic Endocrine Tumor Drug Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Pancreatic Endocrine Tumor Drug Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Pancreatic Endocrine Tumor Drug Price by Type (2021-2032)
  5. 12.2 SAMEA Pancreatic Endocrine Tumor Drug Market Size by Application
  6. 12.2.1 SAMEA Pancreatic Endocrine Tumor Drug Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Pancreatic Endocrine Tumor Drug Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Pancreatic Endocrine Tumor Drug Price by Application (2021-2032)
  9. 12.3 SAMEA Pancreatic Endocrine Tumor Drug Market Size by Country
  10. 12.3.1 SAMEA Pancreatic Endocrine Tumor Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Pancreatic Endocrine Tumor Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Pancreatic Endocrine Tumor Drug Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Pancreatic Endocrine Tumor Drug Value Chain Analysis
  2. 13.1.1 Pancreatic Endocrine Tumor Drug Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Pancreatic Endocrine Tumor Drug Production Mode & Process
  6. 13.2 Pancreatic Endocrine Tumor Drug Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Pancreatic Endocrine Tumor Drug Distributors
  9. 13.2.3 Pancreatic Endocrine Tumor Drug Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst